• Armand R J Girbes, Albert Beishuizen, and Rob J M Strack van Schijndel.
• University Hospital VU Medical Centre, Amsterdam, The Netherlands. arj.girbes@vumc.nl
• Fundam Clin Pharmacol. 2008 Aug 1;22(4):355-61.

AbstractThe incidence of sepsis, the combination of a systemic inflammatory response syndrome and documented infection, is as high as up to 95 cases per 100,000 people per year. The understanding of the pathophysiology of sepsis has much increased over the last 20 years. However, sepsis combined with shock is still associated with a high mortality rate varying from 35 to 55%. Causative treatment, source control and antibiotics started as soon as possible, are the cornerstone of therapy in combination with symptomatic treatment in the ICU. The pharmacological interventions, including fluid resuscitation, vasoactive drugs and adjunctive drugs such as steroids, activated protein C are discussed. The possible beneficial role of strict glucose control is also addressed. Since many drug intervention studies were negative, lessons should be learned from earlier experiences for future trials. Source control and level of intensive care should be eliminated as confounders.

21 keywords...

hide…